Review



plsda models  (MathWorks Inc)


Bioz Verified Symbol MathWorks Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    MathWorks Inc plsda models
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Models, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda models/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    plsda models - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD"

    Article Title: Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD

    Journal: Cellular and Molecular Bioengineering

    doi: 10.1007/s12195-019-00567-2

    A one latent variable PLSDA model of VIP-selected proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Figure Legend Snippet: A one latent variable PLSDA model of VIP-selected proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.

    Techniques Used: Biomarker Discovery

    VIP scores and PLSDA identified a signature of 7 serum proteins that differentiated stable from exacerbation measurements in 16 paired stable and AE-COPD events experienced by 11 unique patients. (a) VIP scores identified a 7-protein serum signature that differentiated stable (purple) and exacerbation (orange) events with 81.25% cross-validation accuracy and 84.38% calibration accuracy. Latent variable 1 (LV1) accounted for 25.00% of the variance in the data, and latent variable 2 (LV2) accounted for 16.75% of the variance in the data. (b) The loadings plot shows how much each protein contributes to the signature, with positive loadings associated with exacerbation events, and negative loadings comparatively reduced in exacerbation. (c) Comparison of the differentiation between stable and exacerbated states based on individual factors vs. multivariate signatures. The VIP signature identified by the PLSDA models trended towards higher cross-validation accuracy than individual factors that were most significantly different. A one-way ANOVA determined that this signature was significantly better than IL-15 alone, with ** indicating a p value less than 0.01 after Tukey’s test for multiple comparisons. (d) Comparison of the calibration accuracies for individual factors vs. the VIP signature identified by the PLSDA model.
    Figure Legend Snippet: VIP scores and PLSDA identified a signature of 7 serum proteins that differentiated stable from exacerbation measurements in 16 paired stable and AE-COPD events experienced by 11 unique patients. (a) VIP scores identified a 7-protein serum signature that differentiated stable (purple) and exacerbation (orange) events with 81.25% cross-validation accuracy and 84.38% calibration accuracy. Latent variable 1 (LV1) accounted for 25.00% of the variance in the data, and latent variable 2 (LV2) accounted for 16.75% of the variance in the data. (b) The loadings plot shows how much each protein contributes to the signature, with positive loadings associated with exacerbation events, and negative loadings comparatively reduced in exacerbation. (c) Comparison of the differentiation between stable and exacerbated states based on individual factors vs. multivariate signatures. The VIP signature identified by the PLSDA models trended towards higher cross-validation accuracy than individual factors that were most significantly different. A one-way ANOVA determined that this signature was significantly better than IL-15 alone, with ** indicating a p value less than 0.01 after Tukey’s test for multiple comparisons. (d) Comparison of the calibration accuracies for individual factors vs. the VIP signature identified by the PLSDA model.

    Techniques Used: Biomarker Discovery, Comparison

    A one latent variable PLSDA model based on two rounds of VIP selection from serum and sputum proteins and blood flow markers shows clear differentiation between stable and exacerbation events across 8 pairs of patient samples, which included 7 paired stable and AE-COPD events experienced by 6 unique patients and one stable and one exacerbation measurement that were not patient matched. (a) PLSDA and two rounds of VIP analysis identified a signature of eleven factors that differentiated the stable (purple) from the exacerbation (orange) events, with 87.5% calibration and cross-validation accuracy. Latent variable 1 (LV1) accounted for 41.51% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot highlights factor contributions to the VIP-selected signature, with positive loadings positively associated with AE-COPD, and negative loadings comparatively reduced during an exacerbation event.
    Figure Legend Snippet: A one latent variable PLSDA model based on two rounds of VIP selection from serum and sputum proteins and blood flow markers shows clear differentiation between stable and exacerbation events across 8 pairs of patient samples, which included 7 paired stable and AE-COPD events experienced by 6 unique patients and one stable and one exacerbation measurement that were not patient matched. (a) PLSDA and two rounds of VIP analysis identified a signature of eleven factors that differentiated the stable (purple) from the exacerbation (orange) events, with 87.5% calibration and cross-validation accuracy. Latent variable 1 (LV1) accounted for 41.51% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot highlights factor contributions to the VIP-selected signature, with positive loadings positively associated with AE-COPD, and negative loadings comparatively reduced during an exacerbation event.

    Techniques Used: Selection, Biomarker Discovery



    Similar Products

    90
    TIBCO plsda model statistica 13.3
    Plsda Model Statistica 13.3, supplied by TIBCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda model statistica 13.3/product/TIBCO
    Average 90 stars, based on 1 article reviews
    plsda model statistica 13.3 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Umetrics plsda modeling simca14.1
    Plsda Modeling Simca14.1, supplied by Umetrics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda modeling simca14.1/product/Umetrics
    Average 90 stars, based on 1 article reviews
    plsda modeling simca14.1 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Wolters Kluwer Health plsda model
    Plsda Model, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda model/product/Wolters Kluwer Health
    Average 90 stars, based on 1 article reviews
    plsda model - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc plsda models
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Models, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda models/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    plsda models - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Eigenvector Research Inc plsda models
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Models, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda models/product/Eigenvector Research Inc
    Average 90 stars, based on 1 article reviews
    plsda models - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Eigenvector Research Inc plsda model
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Model, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda model/product/Eigenvector Research Inc
    Average 90 stars, based on 1 article reviews
    plsda model - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc plsda modeling, permutation testing, and feature selection
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Modeling, Permutation Testing, And Feature Selection, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda modeling, permutation testing, and feature selection/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    plsda modeling, permutation testing, and feature selection - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Stemina Biomarker Discovery plsda classifier model
    A one latent variable <t>PLSDA</t> model <t>of</t> <t>VIP-selected</t> proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.
    Plsda Classifier Model, supplied by Stemina Biomarker Discovery, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plsda classifier model/product/Stemina Biomarker Discovery
    Average 90 stars, based on 1 article reviews
    plsda classifier model - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    A one latent variable PLSDA model of VIP-selected proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.

    Journal: Cellular and Molecular Bioengineering

    Article Title: Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD

    doi: 10.1007/s12195-019-00567-2

    Figure Lengend Snippet: A one latent variable PLSDA model of VIP-selected proteins from the combined serum and sputum samples combined resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD events experienced by 7 unique patients. (a) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation (orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation.

    Article Snippet: All PLSDA models, VIP scores, Wilcoxon signed rank tests, hierarchical clusters, heat maps, and Spearman correlation testing were created or calculated using MATLAB (MATLAB, Natick, MA); PLSDA models and VIP scores were specifically generated using the PLS toolbox in MATLAB (Eigenvector, Manson, WA).

    Techniques: Biomarker Discovery

    VIP scores and PLSDA identified a signature of 7 serum proteins that differentiated stable from exacerbation measurements in 16 paired stable and AE-COPD events experienced by 11 unique patients. (a) VIP scores identified a 7-protein serum signature that differentiated stable (purple) and exacerbation (orange) events with 81.25% cross-validation accuracy and 84.38% calibration accuracy. Latent variable 1 (LV1) accounted for 25.00% of the variance in the data, and latent variable 2 (LV2) accounted for 16.75% of the variance in the data. (b) The loadings plot shows how much each protein contributes to the signature, with positive loadings associated with exacerbation events, and negative loadings comparatively reduced in exacerbation. (c) Comparison of the differentiation between stable and exacerbated states based on individual factors vs. multivariate signatures. The VIP signature identified by the PLSDA models trended towards higher cross-validation accuracy than individual factors that were most significantly different. A one-way ANOVA determined that this signature was significantly better than IL-15 alone, with ** indicating a p value less than 0.01 after Tukey’s test for multiple comparisons. (d) Comparison of the calibration accuracies for individual factors vs. the VIP signature identified by the PLSDA model.

    Journal: Cellular and Molecular Bioengineering

    Article Title: Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD

    doi: 10.1007/s12195-019-00567-2

    Figure Lengend Snippet: VIP scores and PLSDA identified a signature of 7 serum proteins that differentiated stable from exacerbation measurements in 16 paired stable and AE-COPD events experienced by 11 unique patients. (a) VIP scores identified a 7-protein serum signature that differentiated stable (purple) and exacerbation (orange) events with 81.25% cross-validation accuracy and 84.38% calibration accuracy. Latent variable 1 (LV1) accounted for 25.00% of the variance in the data, and latent variable 2 (LV2) accounted for 16.75% of the variance in the data. (b) The loadings plot shows how much each protein contributes to the signature, with positive loadings associated with exacerbation events, and negative loadings comparatively reduced in exacerbation. (c) Comparison of the differentiation between stable and exacerbated states based on individual factors vs. multivariate signatures. The VIP signature identified by the PLSDA models trended towards higher cross-validation accuracy than individual factors that were most significantly different. A one-way ANOVA determined that this signature was significantly better than IL-15 alone, with ** indicating a p value less than 0.01 after Tukey’s test for multiple comparisons. (d) Comparison of the calibration accuracies for individual factors vs. the VIP signature identified by the PLSDA model.

    Article Snippet: All PLSDA models, VIP scores, Wilcoxon signed rank tests, hierarchical clusters, heat maps, and Spearman correlation testing were created or calculated using MATLAB (MATLAB, Natick, MA); PLSDA models and VIP scores were specifically generated using the PLS toolbox in MATLAB (Eigenvector, Manson, WA).

    Techniques: Biomarker Discovery, Comparison

    A one latent variable PLSDA model based on two rounds of VIP selection from serum and sputum proteins and blood flow markers shows clear differentiation between stable and exacerbation events across 8 pairs of patient samples, which included 7 paired stable and AE-COPD events experienced by 6 unique patients and one stable and one exacerbation measurement that were not patient matched. (a) PLSDA and two rounds of VIP analysis identified a signature of eleven factors that differentiated the stable (purple) from the exacerbation (orange) events, with 87.5% calibration and cross-validation accuracy. Latent variable 1 (LV1) accounted for 41.51% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot highlights factor contributions to the VIP-selected signature, with positive loadings positively associated with AE-COPD, and negative loadings comparatively reduced during an exacerbation event.

    Journal: Cellular and Molecular Bioengineering

    Article Title: Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD

    doi: 10.1007/s12195-019-00567-2

    Figure Lengend Snippet: A one latent variable PLSDA model based on two rounds of VIP selection from serum and sputum proteins and blood flow markers shows clear differentiation between stable and exacerbation events across 8 pairs of patient samples, which included 7 paired stable and AE-COPD events experienced by 6 unique patients and one stable and one exacerbation measurement that were not patient matched. (a) PLSDA and two rounds of VIP analysis identified a signature of eleven factors that differentiated the stable (purple) from the exacerbation (orange) events, with 87.5% calibration and cross-validation accuracy. Latent variable 1 (LV1) accounted for 41.51% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (b) The loadings plot highlights factor contributions to the VIP-selected signature, with positive loadings positively associated with AE-COPD, and negative loadings comparatively reduced during an exacerbation event.

    Article Snippet: All PLSDA models, VIP scores, Wilcoxon signed rank tests, hierarchical clusters, heat maps, and Spearman correlation testing were created or calculated using MATLAB (MATLAB, Natick, MA); PLSDA models and VIP scores were specifically generated using the PLS toolbox in MATLAB (Eigenvector, Manson, WA).

    Techniques: Selection, Biomarker Discovery